OligoProgressive Metastatic Disease Clinical Trials

7 recruiting

OligoProgressive Metastatic Disease Trials at a Glance

7 actively recruiting trials for oligoprogressive metastatic disease are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Toronto, Ghent, and Groningen. Lead sponsors running oligoprogressive metastatic disease studies include University Health Network, Toronto, British Columbia Cancer Agency, and Jules Bordet Institute.

Browse oligoprogressive metastatic disease trials by phase

Treatments under study

About OligoProgressive Metastatic Disease Clinical Trials

Looking for clinical trials for OligoProgressive Metastatic Disease? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new OligoProgressive Metastatic Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about OligoProgressive Metastatic Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Not Applicable

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

Metastatic MelanomaOligoProgressive Metastatic Disease
University Health Network, Toronto52 enrolled1 locationNCT07112170
Recruiting
Not Applicable

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

OligoProgressive Metastatic Disease
Jules Bordet Institute48 enrolled5 locationsNCT06925984
Recruiting
Not Applicable

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Oligometastatic DiseaseOligoProgressive Metastatic DiseaseOligoprogression
British Columbia Cancer Agency194 enrolled1 locationNCT06918951
Recruiting
Phase 2Phase 3

A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)

OligoProgressive Metastatic Disease
M.D. Anderson Cancer Center400 enrolled1 locationNCT06367972
Recruiting
Phase 2

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

OligoProgressive Metastatic DiseaseCastrate Resistance Prostate Cancer
University Health Network, Toronto75 enrolled1 locationNCT06927635
Recruiting
Phase 3

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

RadiotherapyOligoProgressive Metastatic DiseaseHepatocellular Carcinoma (HCC)+1 more
Shandong Cancer Hospital and Institute132 enrolled1 locationNCT06841172
Recruiting
Phase 2

The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)

RadiotherapyOligoProgressive Metastatic DiseaseProstate Cancer (Adenocarcinoma)+1 more
University Medical Center Groningen35 enrolled2 locationsNCT07038304